Article Details

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris ...

Retrieved on: 2021-07-29 12:11:15

Tags for this article:

Click the tags to see associated articles and topics

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris .... View article details on HISWAI: https://markets.businessinsider.com/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210

Excerpt

Atreca Shares Slump On Cancer Drug Data. Atreca, Inc. (NASDAQ:BCEL) announced initial data from the dose escalation portion of its ongoing ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up